The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 07, 2008
Filed:
Nov. 15, 2006
Ramani R. Bandarage, Newton, MA (US);
Upul K. Bandarage, Lexington, MA (US);
Xinqin Fang, Lexington, MA (US);
David S. Garvey, Dover, MA (US);
L. Gordon Letts, Dover, MA (US);
Joseph D. Schroeder, Minneapolis, MA (US);
Sang W. Tam, Dover, MA (US);
Ramani R. Bandarage, Newton, MA (US);
Upul K. Bandarage, Lexington, MA (US);
Xinqin Fang, Lexington, MA (US);
David S. Garvey, Dover, MA (US);
L. Gordon Letts, Dover, MA (US);
Joseph D. Schroeder, Minneapolis, MA (US);
Sang W. Tam, Dover, MA (US);
NitroMed, Inc., Lexington, MA (US);
Abstract
The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.